This Study assesses the analgesic and anti-inflammatory activity of a standardized whole-plant CBM with defined ratios and dosages of THC and CBD in a cohort of rheumatoid patients, with the disease of extended duration and with poor analgesic control. A significant analgesic effect was observed and disease activity was significantly suppressed. The study conducted was a double-blind, randomized and placebo study.
Whilst the differences are small and variable across the population, they represent benefits of clinical relevance and indicate the need for more detailed study of dosage, formulation, and ideal patient subgroup. The suppression of pain on movement, the primary endpoint, suggests a peripheral analgesic action.
The suppression of pain at rest may suggest a more central effect. The modest suppression of the present gold standard inflammation activity measure, the DAS28, might indicate an influence on the immune effector system.
Here is the full scientific article if you wish to download it.
The improvement in sleep, a relevant clinical bonus, was probably due mainly to nocturnal symptom relief rather than a specific hypnotic effect since this was not observed in a sleep laboratory study. There was no effect on morning stiffness, but baseline scores were surprisingly low. The trial did not demonstrate significant toxicity and CBM was generally well tolerated.
It is believed that this to be the first controlled study of a CBM in rheumatoid arthritis, and the results are encouraging. More extensive, more prolonged studies of CBM in rheumatoid arthritis are indicated. The study concluded that after patients were treated with Sativex, the disease activity was suppressed significantly. This decrease is giving people with Rheumatoid arthritis pain hope. It’s also important to note that Sativex was administrated by an oromucosal spray. The Sativex medication also had equal amounts of THC and CBD, or as close as researchers could possibly get (2.7 mg THC and 2.5 mg CBD).